Published in Eur J Clin Pharmacol on July 01, 1979
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med (1993) 4.61
Drug treatment of dyslipidemias: practical guidelines for the primary care physician. Heart Dis Stroke (1994) 2.68
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med (1967) 1.97
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther (2001) 1.65
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol (1998) 1.56
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med (1994) 1.46
The meetabolism of amiloride hydroloride in man. Clin Pharmacol Ther (1969) 1.33
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract (2003) 1.19
Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest (1971) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
L-dopa treatment failure: explanation and correction. Br Med J (1970) 0.95
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol (1994) 0.92
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med (1999) 0.89
Evaluation of written reinforcements used in counseling cardiovascular patients. Am J Hosp Pharm (1976) 0.89
Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med (1991) 0.88
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med (1987) 0.88
The instability of isoniazid and acetylisoniazid in frozen plasma. Res Commun Chem Pathol Pharmacol (1976) 0.86
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
Toxicity of a hepatotoxic laxative preparation in tissue culture and excretion in bile in man. Clin Pharmacol Ther (1972) 0.86
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Drug interactions with fibric acids. Pharmacol Ther (1994) 0.85
Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism (1993) 0.85
Pharmacokinetic evaluation of technetium-99-metallothionein-conjugated mouse monoclonal antibody B72.3 in rhesus monkeys. J Nucl Med (1989) 0.84
L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. Biochem Pharmacol (1971) 0.83
Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J Am Coll Nutr (1991) 0.83
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis (1986) 0.83
Enterohepatic circulation of sulindac and metabolites. Clin Pharmacol Ther (1983) 0.83
Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther (1980) 0.82
Quantitation of biliary excretion of drugs in man. Clin Pharmacol Ther (1982) 0.82
Drug interactions of lipid-altering drugs. Drug Saf (1998) 0.82
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis (2000) 0.82
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol (2000) 0.81
Methods to assess relative reliability of diet records: minimum records for monitoring lipid and caloric intake. J Am Diet Assoc (1986) 0.81
Dual hepatic metabolism of cerivastatin--clarifications. Am J Cardiol (1999) 0.81
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
Drug-induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med (1982) 0.80
Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial. Ann Intern Med (1988) 0.80
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis (1988) 0.80
Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemic and normal subjects. Arch Intern Med (1986) 0.80
Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther (1990) 0.80
Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J Lab Clin Med (1972) 0.79
Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol. Clin Pharmacol Ther (1984) 0.79
A clinical pharmacologist's view of drug hepatotoxicity. Pharmacol Res Commun (1977) 0.79
Hepatotoxicity of phenothiazines in vitro as measured by loss of aminotransferases to surrounding media. Proc Soc Exp Biol Med (1968) 0.79
Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. J Cardiovasc Pharmacol (1997) 0.79
Effect of technetium Tc 99m pertechnetate on bacterial survival in solution. Am J Hosp Pharm (1983) 0.78
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 0.78
Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. Biochem Pharmacol (1978) 0.78
Liver cell culture toxicity and surfactant potency of erythromycin derivatives. Toxicol Appl Pharmacol (1975) 0.78
Comparative clinical therapeutic trial with two hypolipidemic drugs: lofibrate and nafenopin. Clin Pharmacol Ther (1971) 0.78
Probucol. Curr Atheroscler Rep (2000) 0.78
The correlation of serum levels of two transaminases with tissue levels in six vertebrate species. Comp Biochem Physiol (1968) 0.78
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol (1995) 0.77
The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man. Thromb Res (1990) 0.77
Chlorpromazine uptake by isolated rat hepatocytes. Proc Soc Exp Biol Med (1979) 0.77
Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol (2001) 0.76
Omega-3 fatty acids in hypertriglyceridemic patients: triglycerides vs methyl esters. Am J Clin Nutr (1988) 0.76
Cytotoxicity of phenothiazines on Chang liver cells as measured by enzyme leakage. Proc Soc Exp Biol Med (1969) 0.76
One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther (1976) 0.76
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis (1995) 0.76
Liver cell culture toxicity of general anesthetics. Toxicol Appl Pharmacol (1976) 0.75
Lipid-altering drugs in development. Drugs R D (1999) 0.75
Clinical radiopharmacy: principles and practices. Semin Nucl Med (1996) 0.75
The effect of cyclosporine concentration on the labeling efficiency of an in vitro technetium-99m red blood cell labeling procedure. J Nucl Med Technol (1997) 0.75
Colestipol and clofibrate in hypercholesterolemia. Clin Pharmacol Ther (1974) 0.75
Ethical, medical and legal issues for the use of placebos in future lipid intervention trials. Curr Opin Lipidol (2001) 0.75
Elevated lipoprotein (a) blood levels as the single treatable atherosclerotic risk factor in patients with coronary artery disease. J Ky Med Assoc (1993) 0.75
Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients. Clin Pharmacol Ther (1970) 0.75
Changes in liver and spleen scans of patients during treatment with two hypolipidemic drugs. Radiology (1971) 0.75
Toxicity of hepatotoxic drugs on mouse liver tissue culture. Arch Int Pharmacodyn Ther (1970) 0.75
Tumors potentiating catecholamine-induced hypertension. Life Sci I (1971) 0.75
The correlation between serum and tissue levels of enzymes in six vertebrate species--studies on lactate dehydrogenase, phosphohexose isomerase, aldolase and malate dehydrogenase. Comp Biochem Physiol (1969) 0.75
Failure to label red blood cells adequately in daily practice using an in vivo method: methodological and clinical considerations [1]. Eur J Nucl Med (1998) 0.75
Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority. Postgrad Med (1992) 0.75
Technetium antimony sulfur colloid scintiscan in selective lymph node dissection for malignant melanoma. J Dermatol Surg Oncol (1986) 0.75
Relationship between surface activity and toxicity to Chang liver cultures of tricyclic antidepressants. Pharmacology (1979) 0.75
The treatment of hyperlipoproteinemias. Ration Drug Ther (1979) 0.75
Common uses of nonradioactive drugs in nuclear medicine. Am J Hosp Pharm (1984) 0.75
Potential role of hospital pharmacy in the handling and distribution of diagnostic radiopharmaceuticals. Am J Hosp Pharm (1990) 0.75
Post-traumatic pulmonary accumulation of Tc-99m sulfur colloid. J Nucl Med (1982) 0.75
A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients. Am J Med Sci (1979) 0.75
Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol (1984) 0.75
The effects of selected antineoplastic agents on the labeling of erythrocytes with technetium-99m using the UltraTag RBC kit. J Nucl Med Technol (1999) 0.75
The European (EAS) and the American (NCEP) cholesterol guidelines: are they still adequate? Postgrad Med J (1989) 0.75
Experimental investigations on the different hepatotoxic potential of erythromycin derivatives. Med Chir Dig (1976) 0.75
Interaction of mestranol with taurocholate uptake by isolated rat hepatocytes. Res Commun Chem Pathol Pharmacol (1979) 0.75
Surface activity, cellular uptake and cytotoxicity of tricyclic psychoactive drugs in vitro. Biochem Pharmacol (1979) 0.75
Hepatotoxicity and surface activity of tricyclic antidepressants in vitro. Toxicol Appl Pharmacol (1979) 0.75
Clinical trial design for obesity agents: a workshop report. Obes Res (1998) 0.75
Hepatocyte responses to volatile anesthetics: changes in surface scanning and enzyme leakage. Anesth Analg (1979) 0.75
The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study. Am J Cardiol (1997) 0.75
A study of the concept of non-radioactive unit-dosed reagent kits [cold unit doses (CUDs)] as an efficient and cost-saving method for 99mTc radiopharmaceutical preparation. Int J Rad Appl Instrum B (1992) 0.75
Calcium and CNS symptoms. N Engl J Med (1969) 0.75
Comparison of two scoring systems used to monitor diets in outpatient clinical trials. J Cardiovasc Risk (1995) 0.75
Alterations of liver-cell membranes after exposure to halothane. N Engl J Med (1980) 0.75
Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems. Pharmacology (1980) 0.75
AHA Conference Report on Cholesterol. Drug therapy. Circulation (1989) 0.75
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Prog Drug Res (1994) 0.75